 WALTHAM, Mass., Sept. 23, 2021 GLOBE NEWSWIRE -- Viridian Therapeutics, Inc. NASDAQ: VRDN, a biopharmaceutical company advancing new treatments for patients suffering from serious diseases but underserved by todays therapies, today announced the closing of an underwritten public offering of 7,344,543 shares of common stock, which includes the exercise in full by the underwriters of their option to purchase up to 1,159,089 additional shares of common stock, at a public offering price of 11.00 per share and 23,126 shares of series B preferred stock the Series B Preferred at a public offering price of 733.37 per share, which are convertible into approximately 1,541,810 shares of common stock, subject to beneficial ownership conversion limits. The gross proceeds of the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Viridian, were approximately 97.7 million. 